Quince Therapeutics to Acquire EryDel
Quince is pleased to announce that it has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company with an innovative autologous intracellular drug encapsulation (AIDE) technology and a Phase 3 lead asset, EryDex.
EryDex targets a rare fatal pediatric neurological disease, Ataxia-Telangiectasia, which currently has no approved treatments and represents an estimated $1+ billion peak sales opportunity.
Learn more about the EryDel acquisition.